Business Parks & Science Centres



Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
All >

Deals > A Fine Selection by [iito]

[ # 12 & 35 ]
Find below a fine selection of interesting & curious, important & meaningless deals by [iito] Business Intelligence

Total search results: 354 | Ordered by Date (descending)
1 2 3 4  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners 2019-01-30
MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
Argen-X–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion 2018-11-02
Endocyte–Novartis: investment, 201810– acquisition $2.1b in cash of Endocyte by Novartis ANNOUNCED 2018-10-18
LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi 2018-10-12
Gotham Therapeutics–SEVERAL: investment, 201810 financing round Series A $54m co-led by Versant Ventures + Forbion + SR One 2018-10-10
Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners 2018-10-08
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics 2018-09-28
CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share 2018-09-19
Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech 2018-08-27
NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan 2018-08-16
Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 2018-08-15
United Kingdom (govt)–Bruker Corp: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC 2018-08-06
Foundation Medicine–Roche: investment, 201806–201807 acquisition all remaining shares for $2.4b in cash at $137/share 2018-06-19
Sanofi–Evotec: investment, 201806–201807 acquisition integration of Sanofi’s infectious disease RnD in Lyon into Evotec 2018-06-15
Andrew Alliance–SEVERAL: investment, 201806 financing round Series C $14m incl Tecan + Waters + Inpeco + Rancilio Cube + Sam Eletr + Omega Funds 2018-06-12
Andrew Alliance–Tecan: investment, 201806 financing round Series C totalling $14m incl Tecan Group 2018-06-12
Roche–Microbiotica: microbiomics, 201806– collab multi-year up to $534m r+d + commerc of markers + targets + treatments for IBD w Genentech 2018-06-06
Roivant–Oxford BioMedica: Parkinson’s gene therapy, 201806– license ww excl to OXB-102 $30m upfront + $812.5m milestones to Axovant Sciences 2018-06-06
Gilead–Hookipa: therapeutic vaccine technology, 201806– collab + license $10m upfront r+d immunotherapies against HIV + HBV 2018-06-05
Evotec–I’rom Group: iPSC technology, 201805– license non-excl for iPSCs produced with Sendai virus vector technology from ID Pharma 2018-05-23
Bluebird Bio–Medigene: TCR technology, 201805– collab strategic alliance expansion incl $8m one-time payment 2018-05-14
Armo BioSciences–Lilly: investment, 201805– acquisition $1.6b cash tender offer at $50/share by Eli Lilly 2018-05-10
InflaRx–SEVERAL: investment, 201805 primary public offering $51m+$7.65m w 1.5m+225k common shares at $34/share 2018-05-02
Crescendo Biologics–SEVERAL: investment, 201805 financing round Series B €57m led by Andera Partners 2018-04-30
Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz 2018-04-18
Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform 2018-04-12
Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology 2018-04-11
AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share 2018-04-09
Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share 2018-04-09
Boehringer–OSE Immunotherapeutics: antibody cancer drug, 201804– collab + license ww OSE-172 €30m upfront+short-term + €1.1b milestones + royalties 2018-04-04
LCF Rothschild–Andera Partners: investment, 201804 management buy-out of EdRIP by employees + renaming to Andera Partners 2018-04-04
Novartis–GSK: investment, 201803– acquisition $13b of 36.5% stake of Novartis in OTC joint venture giving GSK 100% ownership 2018-03-27
NMD Pharma–SEVERAL: investment, 201803 financing round Series A €38m led by new investor Inkef Capital + incl RVF + Novo Seeds + Lundbeckfonden 2018-03-23
MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market 2018-03-22
Novartis–Harvard Univ: drug delivery technology, 201803– collab develop biomaterial systems for delivery of cancer immuntherapies NIBR + Wyss + Dana 2018-03-20
Prexton Therapeutics–Lundbeck: investment, 201803– acquisition €100m upfront + €805m developm + sales milestones ANNOUNCED 2018-03-16
Siemens–SEVERAL: investment, 201803 IPO €4.2b of Siemens Healthineers AG at FSE floating 150m (15% of) shares at €28/share 2018-03-16
Atomwise–SEVERAL: investment, 201803 financing round Series A $45m co-led by Monsanto GV + DCVC (Data Collective) + B Capital Group 2018-03-07
Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform 2018-03-05
Aimmune Therapeutics–SEVERAL: investment, 201802–201803 public offering $176m+$26.4m net $190m with 5.5m+825k shares common stock at $32/share 2018-02-20
Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 2018-02-15
Flatiron Health–Roche: investment, 201802–201804 acquisition $1.9b of remaining 87.4% not already owned by Roche 2018-02-15
Pieris–SEVERAL: investment, 201802 public offering $50.6m with 5.5m+825k common shares at $8/share 2018-02-13
Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share 2018-02-12
Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins 2018-02-09
Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases 2018-02-06
STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen 2018-01-31
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Novartis–Spark Therapeutics: voretigene neparvovec, 201801– license ww outside US to develop + register + commerc gene therapy Luxtarna 2018-01-24
High-Tech Gründerfonds–Dräger: investment, 201801 investment of Dräger in HTGF III Fund 2018-01-23
Juno Therapeutics–Celgene: investment, 201801–201803 acquisition cash tender offer $9b net of cash + shares already owned by Celgene $87/share 2018-01-22
Novartis–Biocon: biosimilars, 201801– collab strategic ww excl developm + production + comercialisation Sandoz + Biocon 2018-01-18
Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte 2018-01-11
Structural Genomics Consortium–Enamine: chemical compound libraries, 201801– supply new generation of Diamond-SGC-iNEXT (DSI) Poised Library 2018-01-10
General Electric–Roche: diagnostics, 201801– collab developm integrated digital + IVD + in vivo diagnostics platform for oncology + critical care 2018-01-08
TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share 2018-01-05
CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system 2018-01-04
CRISPR Therapeutics–SEVERAL: investment, 201801 public offering $113.75m of 5m+750k common shares at $22.75/share 2018-01-03
Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share 2017-12-21
Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties 2017-12-20
Boehringer–Autifony: CNS drugs, 201712– collab €25m upfront + up to total of €627.5m excl option to acquire KV3.1/3.2 positive modulators for BI 2017-12-18
NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures 2017-12-12
Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+ 2017-12-11
JnJ–Idorsia: aprocitentan, 201712– collab developm + license ww commerc for Janssen $230m upfront + royalties 20–35% 2017-12-04
I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties 2017-11-30
Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche 2017-11-17
Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech 2017-11-15
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195 2017-11-14
CRISPR Therapeutics–CureVac: mRNA technology, 201711– collab + license using RNArt techn to develop in-vivo gene-editing programs in liver diseases 2017-11-13
InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market 2017-11-10
Boehringer–MiNA Therapeutics: RNAa drugs, 201711– collab up to €307m plus royalties developm of RNAa drugs for fibrotic liver diseases incl NASH 2017-11-08
NousCom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures 2017-11-06
Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share 2017-10-30
Lilly–CureVac: cancer vaccines, 201710– collab ww $50m upfront + $45m equity investment + $1.7b milestones up to 5 products using RNActive technology 2017-10-18
SurgVision–Bracco: investment, 201710 acquisition of SurgVision BV by Bracco Imaging SpA 2017-10-18
Roche–Warp Drive Bio: drug discovery, 201710– strategic collab up to $387m plus royalties r+d of novel antibiotics using Genome Mining platform 2017-10-16
Kohlberg Kravis Roberts–Eurofins: investment, 201710– acquisition of LGC Forensics division of LGC Group from KKR 2017-10-12
Nestlé–Codexis: therapeutic enzymes, 201710– collab strategic alliance using CodeEvolver platform + incl option for ww developm of CDX-6114 2017-10-12
Exscientia–Evotec: investment, 201709 investment €15m by Evotec AG to acquire minority stake in Exscientia Ltd 2017-09-28
Novartis–Univ California: drug discovery technology, 201709– collab establishment of Novartis-Berkeley Center for Proteomics & Chemistry Technologies 2017-09-28
Humabs BioMed–Vir Biotechnology: investment, 201709 acquisition of Humabs by Vir 2017-09-21
Juno Therapeutics–SEVERAL: investment, 201709 public offering $250.1m+$37.515m with 6.1m+915k shares at $41/share 2017-09-20
Axiogenesis–Pluriomics: investment, 201709 merger into Ncardia 2017-09-18
1 2 3 4  next pagenext page


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSUS] – The Business Web Portal 600x60px

» top